Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn if BMS-512148 (Dapagliflozin) as part of a triple
combination therapy can improve (decrease) hemoglobin A1c in patients with type 2 diabetes
after 24 weeks of treatment compared to a 2 drug oral antidiabetic therapy. The safety of
this treatment will also be studied.